By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Pharmacology MentorPharmacology MentorPharmacology Mentor
  • Home
  • Bookmarks
  • Pages
    • Terms and conditions
    • Submit a Topic or Chapter
    • Ask for a topic
    • Copyright Statement
    • Privacy Policy
    • Contact
    • About
  • Quizzes
    • Quiz on Antihyperlipidemics
    • Quiz on Antihypertensives
    • Quiz on Antiarrhythmics
    • Quiz on Drugs for CCF
    • Practice Quizzes on Antidiabetic drugs
    • Practice Quizzes on Drugs used in GI Disorders
    • CVS Post lab Quiz
    • Quiz on Pharmacokinetics and Pharmacodynamics
    • Drugs acting on CNS – All CNS topics EXCEPT NSAIDs
    • Drugs acting on ANS
    • Antimicrobial Chemotherapy: Antiprotozoal and antihelminthic drugs
    • Antimicrobial Chemotherapy – Antimalarial Drugs
    • Antimicrobial Chemotherapy – Antiviral and antifungal drugs
    • OC Pills
    • Antimicrobial Chemotherapy – Antibacterials
    • Quizzes at MedQuizzify
  • Blog
  • Chapters
    • General
    • CVS
    • Antimicrobial
    • Neuropharmacology
    • ANS
    • PNS
    • GI
    • Endocrine
    • Hematology
    • miscellaneous
  • Drug Monographs
Search
  • Advertise
© 2024 Pharmacology Mentor. All Rights Reserved.
Reading: Antiarrhythmic drugs: Mexiletine (Class 1B)
Share
Sign In
Notification Show More
Font ResizerAa
Pharmacology MentorPharmacology Mentor
Font ResizerAa
Search
  • Home
  • Blog
  • Bookmarks
  • Terms and conditions
  • Submit a Topic or Chapter
  • Ask for a topic
  • Copyright Statement
  • Contact
  • Quizzes
    • Quiz on Antihyperlipidemics
    • Quiz on Antiarrhythmics
    • Quiz on Drugs for CCF
    • Quiz on Antihypertensives
    • Practice Quizzes on Antidiabetic drugs
    • Practice Quizzes on Drugs used in GI Disorders
    • Quiz on Pharmacokinetics and Pharmacodynamics
    • Drugs acting on CNS – All CNS topics EXCEPT NSAIDs
    • NSAIDs
    • CVS Post lab Quiz
    • Drugs acting on ANS
    • Antimicrobial Chemotherapy – Antimalarial Drugs
    • Antimicrobial Chemotherapy: Antiprotozoal and antihelminthic drugs
    • Antimicrobial Chemotherapy – Antiviral and antifungal drugs
    • OC Pills
    • Antimicrobial Chemotherapy – Antibacterials
  • About
Have an existing account? Sign In
Follow US
  • Advertise
© 2024 Pharmacology Mentor. All Rights Reserved.
Pharmacology Mentor > Blog > Pharmacology > CVS > Antiarrhythmic drugs: Mexiletine (Class 1B)
CVSPharmacology

Antiarrhythmic drugs: Mexiletine (Class 1B)

Last updated: 2025/09/11 at 4:01 AM
Pharmacology Mentor 4 Views
Share
9 Min Read
Mexiletine
#Mexiletine
SHARE

Mexiletine is an oral Class IB antiarrhythmic and sodium channel blocker structurally related to lidocaine, used primarily for ventricular arrhythmias and selected channelopathies such as LQT3 where late sodium current inhibition is desired.
Its key antiarrhythmic actions are fast-on/fast-off block of fast Na+ channels with preference for inactivated channels in ischemic tissue, leading to rate‑dependent suppression of ventricular ectopy with minimal effect at normal heart rates.

Contents
ClassificationMechanismElectrophysiologyPharmacokineticsIndications and roleDosing and administrationContraindications and cautionsAdverse effectsDrug interactionsSpecial populationsMonitoringClinical pearlsComparison to other Class I agentsPractical initiation checklist

Classification

  • Class IB antiarrhythmic (Vaughan–Williams), sodium-channel blocker with rapid kinetics and high preference for inactivated channels.
  • Distinct from Class IA/IC: produces minimal QRS widening at therapeutic doses and tends to shorten action potential duration (APD) in ventricular myocardium.

Mechanism

  • Blocks voltage‑gated fast Na+ channels during phase 0 in fast-response tissues, more avidly in depolarized/ischemic myocardium where channels dwell in the inactivated state.
  • Decreases slope of phase 0 in diseased tissue, shortens APD and effective refractory period (ERP) in Purkinje/ventricular fibers, often increasing the ERP/APD ratio, which can reduce reentry.
  • Inhibits late sodium current (INa,late), which is clinically useful for repolarization abnormalities (e.g., congenital LQT3) by abbreviating repolarization and reducing triggered activity.

Electrophysiology

  • Ventricular tissue: decreases APD and ERP modestly; suppresses automaticity and triggered activity in ischemic regions.
  • Atria/AV node: minimal clinically meaningful effects at therapeutic levels; not a rate‑control or AV nodal drug.
  • ECG: little to no change in QRS or QT at usual doses; mild PR or QRS changes can occur at higher concentrations; QT shortening may be observed in LQT3.
Mexiletine
#Mexiletine MOA

Pharmacokinetics

  • Oral bioavailability high (approximately 85–90%); onset within hours, enabling chronic outpatient use.
  • Peak concentration typically 2–4 hours for immediate‑release; controlled‑release products exist in some regions.
  • Volume of distribution moderate; protein binding ~50–60%.
  • Hepatic metabolism predominates (CYP2D6 major; CYP1A2 contributory); active metabolites are minimal contributors in most patients.
  • Elimination half‑life roughly 10–12 hours; renal excretion of parent drug is limited (~10%), so renal impairment has modest effect compared with hepatic impairment.

Indications and role

  • Documented, clinically significant ventricular arrhythmias: sustained VT, symptomatic non‑sustained VT, frequent PVCs with symptoms or cardiomyopathy concern when first‑line strategies fail or are not tolerated.
  • Adjunct in structural heart disease, particularly ischemic substrates, to reduce VT burden and ICD shocks when beta‑blockers and/or amiodarone are insufficient or poorly tolerated.
  • Channelopathies: useful in congenital LQT3 and in acquired scenarios with increased late INa to shorten QT and reduce torsadogenic triggers.
  • Not a first‑line agent for supraventricular arrhythmias and not indicated for rate control.

Dosing and administration

  • Typical adult start: 150–200 mg orally every 8 hours with food to minimize GI upset.
  • Usual maintenance range: 200–300 mg every 8 hours (total daily 450–900 mg), adjusted by response and tolerability; some patients use 250–300 mg every 12 hours in extended‑release formulations where available.
  • Titration: increase every 2–3 days based on symptom/arrhythmia surveillance, side effects, and ECG.
  • Hepatic impairment or poor CYP2D6 metabolizers: consider lower starting dose (e.g., 50–100 mg every 8–12 hours) and slower titration.
  • Take with meals or antacid to reduce dyspepsia, nausea, and epigastric discomfort.

Contraindications and cautions

  • Absolute: cardiogenic shock; second‑/third‑degree AV block or severe sinus node dysfunction without a pacemaker; hypersensitivity to mexiletine or local anesthetic–type agents.
  • Relative/caution: significant hepatic impairment; seizure disorders; persistent severe bradycardia; concomitant drugs that markedly slow conduction or lower seizure threshold; recent MI with ongoing ischemia (specialist management required).
  • Not for asymptomatic PVC suppression in the absence of other indications given historical mortality concerns with Class I agents post‑MI; reserve for carefully selected cases.

Adverse effects

  • Gastrointestinal: nausea, dyspepsia, epigastric pain, vomiting; often dose‑limiting but improved with food or dose splitting.
  • Neurologic: tremor, dizziness, ataxia, paresthesias, blurred vision, insomnia; dose‑related and improve with reduction.
  • Cardiac: bradyarrhythmias or conduction slowing at high levels; proarrhythmia is uncommon compared with IA/IC but can occur, especially with electrolyte imbalance or interacting QT‑active drugs.
  • Hepatic: transaminase elevations (usually mild); rare clinically significant injury.
  • Dermatologic and hypersensitivity reactions are uncommon but possible.

Drug interactions

  • CYP2D6 substrate: strong inhibitors (e.g., fluoxetine, paroxetine, quinidine) can raise levels; poor metabolizers may have higher exposure.
  • CYP1A2: inducers (e.g., smoking) may lower levels; inhibitors (e.g., fluvoxamine, ciprofloxacin) may raise levels.
  • Additive conduction slowing with other membrane‑active antiarrhythmics or high‑dose beta‑blockers; caution with amiodarone (pharmacodynamic and metabolic interactions), lidocaine (overlapping toxicity), and other QT‑active agents even though mexiletine usually shortens QT.
  • Theophylline and other narrow therapeutic index drugs metabolized by CYP1A2 may have bidirectional interactions; monitor levels and effects when co‑administered.

Special populations

  • Hepatic impairment: reduce dose and titrate slowly with close monitoring for neuro/GI toxicity.
  • Renal impairment: usually no major adjustment until severe impairment; monitor for accumulation in combined hepatic/renal dysfunction.
  • Older adults: increased sensitivity to CNS and GI effects; start low and go slow.
  • Pregnancy/lactation: limited human data; use only if benefits justify potential risks and consider alternatives first in non‑life‑threatening scenarios.

Monitoring

  • Baseline and follow‑up ECG for QRS/PR and rhythm burden; ambulatory monitoring (e.g., Holter) to gauge PVC/VT reduction and symptom correlation.
  • Electrolytes (K+, Mg2+), particularly in patients on diuretics or with GI losses; maintain K+ in high‑normal range to mitigate proarrhythmia.
  • Hepatic function at baseline and periodically; consider levels or pharmacogenetic context when toxicity appears out of proportion to dose.
  • Clinical surveillance for neurologic and GI intolerance; adjust dose or dosing frequency accordingly.

Clinical pearls

  • Best suited for ischemia‑related ventricular ectopy/VT because of preferential binding to inactivated Na+ channels prevalent in depolarized tissue.
  • Oral “analogue of lidocaine”: lidocaine for acute IV suppression in the hospital, mexiletine for longer‑term outpatient suppression when appropriate.
  • In LQT3, late INa inhibition can shorten QTc and reduce arrhythmic events; ensure careful ECG follow‑up and avoid concomitant QT‑prolonging triggers.
  • If tremor or GI upset emerges during titration, try food co‑administration, smaller but more frequent dosing, or a modest dose reduction before abandoning therapy.
  • Consider as adjunct to reduce ICD shocks when amiodarone or sotalol are limited by intolerance, bradycardia, or QT effects—often alongside beta‑blockade.

Comparison to other Class I agents

  • Versus Class IA/IC (e.g., quinidine, flecainide, propafenone): lower proarrhythmic risk in structural heart disease and minimal QRS widening at therapeutic doses, but typically less potent for maintaining sinus rhythm in atrial arrhythmias.
  • Versus lidocaine: similar mechanism and ischemia selectivity, but mexiletine is orally bioavailable and suitable for chronic use.

Practical initiation checklist

  • Confirm indication (symptomatic VT/PVCs with impact on quality of life or ICD therapies; selected LQT3) and rule out safer alternatives.
  • Baseline ECG, electrolytes, hepatic function, medication review for CYP2D6/1A2 and QT/conduction interactions.
  • Start low (e.g., 150 mg every 8–12 hours with food), reassess symptoms/ECG in 3–7 days, titrate in 50–100 mg increments per dose.
  • Educate on expected GI/CNS effects, adherence with meals, and when to seek care (syncope, marked dizziness, visual disturbances, persistent vomiting).
  • Reassess efficacy with ambulatory monitoring in 2–6 weeks; continue only if clinically meaningful benefit with acceptable tolerability.

Note: This article is intended for educational purposes and should not be considered as medical advice. Always consult with a healthcare professional for medical advice and treatment.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of a healthcare provider with any questions regarding a medical condition.

You Might Also Like

Steady-State Concentration: Principles, Calculations, and Clinical Application

Drug receptor classes

Over-the-Counter (OTC) Drugs in India: A Comprehensive Overview

Over-the-Counter (OTC) Drugs: A Comprehensive Overview

The Concept of P-Drugs in Rational Prescribing

TAGGED: Mexiletine, Pharmacology

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Previous Article Lidocaine Antiarrhythmic drugs: Lidocaine (Class 1B)
Next Article Flecainide Antiarrhythmic drugs: Flecainide (Class 1C)
1 Review 1 Review
  • Antiarrhythmic Drugs | Pharmacology Mentor says:

    […] IB: Lidocaine, Mexiletine, […]

    Reply

Leave a review Cancel reply

Your email address will not be published. Required fields are marked *

Please select a rating!

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Most Popular Posts

  1. Drug Nomenclature: Drug Naming system (Dr. Ambadasu Bharatha) (673)
  2. Routes of Drug Administration: A detailed overview (Pharmacology Mentor) (652)
  3. Routes of Drug Administration (Pharmacology Mentor) (556)
  4. First-Order vs. Zero-Order Kinetics: What You Need to Know (Pharmacology Mentor) (485)
  5. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Comprehensive Guide (Pharmacology Mentor) (423)
  6. Pharmacology Definitions and Terminology (Pharmacology Mentor) (408)
  7. Antimalarial Drugs – A Comprehensive Guide (Pharmacology Mentor) (349)
  8. Enzyme inducers: How they are important in the clinical pharmacology? (Pharmacology Mentor) (324)
  9. Drug Potency and Efficacy (Pharmacology Mentor) (324)
  10. Pharmacokinetics (ADME): an overview (Pharmacology Mentor) (286)

Categories

  • ANS26
  • Antimicrobial35
  • Clinical Pharmacology4
  • CVS31
  • Endocrine21
  • Featured15
  • General49
  • GI15
  • Hematology13
  • miscellaneous31
  • Neuropharmacology38
  • Pharmacology266
  • PNS2
  • Reproductive System10
  • Respiratory System7

Tags

Adverse effects Antibiotics Antiplatelet Drugs Aspirin Benzodiazepines beta-blockers Bioavailability Bipolar disorder calcium channel blockers Carbamazepine Clinical trials contraindications Coronary artery disease Dosage DRC drug absorption Drug Administration Drug classification drug design Drug development Drug discovery Drug Dosage Drug efficacy Drug formulation Drug interactions Drug metabolism Drug regulation Drugs Drug safety Generic drugs Headache Hypertension mechanism of action Medication Myocardial infarction Neurotransmitters Norepinephrine Pharmacodynamics Pharmacokinetics Pharmacological actions Pharmacology Pharmacovigilance Side effects Therapeutic uses Treatment

Latest Articles

Steady-state concentration
Steady-State Concentration: Principles, Calculations, and Clinical Application
General Pharmacology August 31, 2025
drug receptors
Drug receptor classes
General Pharmacology August 31, 2025
otc drugs
Over-the-Counter (OTC) Drugs in India: A Comprehensive Overview
miscellaneous Pharmacology August 29, 2025
otc drugs
Over-the-Counter (OTC) Drugs: A Comprehensive Overview
miscellaneous Pharmacology August 29, 2025

Stay Connected

Facebook Like
//

Pharmacology Mentor is dedicated to serving as a useful resource for as many different types of users as possible, including students, researchers, healthcare professionals, and anyone interested in understanding pharmacology.

Quick Link

  • Terms and conditions
  • Copyright Statement
  • Privacy Policy
  • Ask for a topic
  • Submit a Topic or Chapter
  • Contact

Top Categories

  • Pharmacology
  • Antimicrobial
  • Neuropharmacology
  • Endocrine
  • Reproductive System
  • miscellaneous

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Pharmacology MentorPharmacology Mentor
Follow US
© 2024 Pharmacology Mentor. All Rights Reserved.
Pharmacology Mentor
Welcome Back!

Sign in to your account

Register Lost your password?